You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Position tracking and mobility assessment system for indoor monitoring of elders

    SBC: EMBEDRF LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The long term objective of this project is to enable elderly persons to independently live within their own homes later into their lives with the assurance that their safety and well-being can be remotely monitored by health care professionals. A critical component of remote health care monitoring is physically tracking the location of the patient within a livi ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Peptidomic Rapid Point-of-Care TB Diagnostic

    SBC: NEW YORK UNIVERSITY            Topic: NIAID

    DESCRIPTION (provided by applicant): The goals of this proposal are to devise rapid serological tests that can replace the sputum smear test for the diagnosis of active TB and meets the WHO specifications to replace microscopy in resource-limited countries based on immunodominant peptides from three M. tb cell-wall proteins. Although direct smear microscopy is highly specific, the test is tedious, ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. A cost-effective bioreactor to advance functional tissue engineering of cartilage

    SBC: Apex Biomedical Company, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develop replacement cartilage using tissue engineering (TE) technologies. Although TE cartilage presently lacks the mechanical stability of native cartilage, studies have demonstrated that mechanical stability can be e ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. MDC-1231 for cancer prevention

    SBC: Medicon            Topic: NCI

    DESCRIPTION (provided by applicant): Strong evidence supports the notion that chemoprevention has the potential to be a major component of colorectal cancer control. The prevention of cancer depends heavily on the development of safe and effective agents. NSAIDs prevent colorectal cancer but have two major limitations that preclude their large-scale application to prevent colorectal cancer: a) sig ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Novel RTL treatment to promote brain repair and cognitive recovery following meth

    SBC: VIROGENOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Methamphetamine (MA) dependence is associated with neuropsychiatric side effects that make the addiction extremely challenging to treat. Patients seeking treatment experience ongoing impairments in cognition, mood, and motivation. Currently, there are no FDA-approved pharmacotherapies for MA dependence. The goal of this proof-of-concept research project is test ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Technology Transfer of the ATLAS and ATHENA Programs

    SBC: Odyssey Science Innovations, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Over 7.5 million high school students participate in high school sports programs and an additional 2 million students join these athletic teams each year. Adolescent athletes are at risk for using performance enhancing drugs, such as anabolic steroids, unregulated sport supplements, and illicit drugs and alcohol. Unfortunately, few evidence-based substance abus ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. TeamChip for High-throughput, Predictive Human Metabolism and Toxicology

    SBC: Solidus Biosciences, Inc.            Topic: NIEHS

    DESCRIPTION (provided by applicant): Solidus Biosciences, Inc. in partnership with Rensselaer Polytechnic Institute is proposing to address a critical need in chemical safety technology through its proprietary Transfected Enzyme and Metabolism Chip (or TeamChip) for high-throughput analysis of systematic drug candidate and chemical metabolism and toxicology. The TeamChip is being developed to mi ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. PROOF OF CONCEPT FOR ANTIMICROBIAL PROPERTIES OF LACRITIN IN VIVO

    SBC: EYERX RESEARCH, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Over the past sixty years, antibiotics have comprised a key component in both the treatment and prophylaxis of bacterial infections. Since that time the continuous development of new antibiotics has been necessary to limit toxicity, promote broader spectrum therapy, increase convenience of use, and decrease the time to clear the infection. Another driving force ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Topical Nanoparticles for CNV

    SBC: NANOTRANS TECHNOLOGIES, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Age Related Macular Degeneration (AMD) is the leading cause of blindness in adults over 50 years. Choroidal neovascularization (CNV), the pathologic creation of new blood vessels in the choroid layer of the eye, is a principal cause of blindness due to AMD. Current therapeutic management of AMD is far from optimal and requires repeated injections in the vitreou ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government